These therapeutic approaches suggest that blocking AREG activity can restore sensitivity to EGFR-targeted therapies in multiple cancer types including colorectal cancer [188,189], lung cancer [42], and pancreatic cancer [190]. This evidence concerns the gene EGFR and cancer.